Condition
    Moderate Evidence
    Effectiveness 2/5

    Omega-3 Fatty Acids for Chronic Kidney Disease

    Omega-3 has reasonable evidence for reducing proteinuria in IgA nephropathy and clear cardiovascular relevance in kidney disease, but it does not reliably slow filtration decline.

    Overview

    Omega-3 has reasonable evidence for reducing proteinuria in IgA nephropathy and clear cardiovascular relevance in kidney disease, but it does not reliably slow filtration decline.

    Verdict

    Mixed evidence

    A defensible adjunct for cardiovascular risk and possibly proteinuria, not a treatment that preserves filtration rate.

    How It Works

    EPA and DHA are incorporated into glomerular and tubular cell membranes, where they compete with arachidonic acid and shift eicosanoid production toward less inflammatory series-3 prostaglandins and resolvins. In the kidney this reduces mesangial inflammatory signalling and may lower intraglomerular pressure through effects on afferent arteriolar tone, mechanisms relevant to proteinuria.

    Dosing & Protocol

    Typical dose

    Recommended dose
    1-2 g combined EPA and DHA daily, with higher doses only under supervision
    Expected timeframe
    Proteinuria changes, where they occur, appear over three to six months. Triglyceride reduction is measurable within eight to twelve weeks.

    Protocol

    form
    Triglyceride-form fish oil or algal oil
    duration
    6-12 months, tracking eGFR, proteinuria and lipids
    co factor
    Take with a meal. Evidence is mixed: fish oil reliably lowers triglycerides, which are commonly raised in CKD, but effects on eGFR decline and proteinuria are inconsistent across trials, with the strongest signal in IgA nephropathy.
    titration
    Up to 2000 mg/day; IgA nephropathy trials used 1.8-3.4 g/day, and dialysis graft-patency trials used around 4 g/day under supervision
    starting dose
    1000 mg combined EPA+DHA daily with food, with the nephrology team informed

    Evidence

    What the studies say

    The best-defined signal is in IgA nephropathy, where the Mayo Clinic trials reported slower renal function decline with fish oil, though subsequent trials and meta-analyses have been inconsistent and current guidelines describe the evidence as weak. Across chronic kidney disease more broadly, Cochrane reviews find omega-3 reduces proteinuria modestly but shows no clear effect on progression to kidney failure or on estimated GFR slope. Cardiovascular outcomes matter greatly in this population, since most people with kidney disease die of cardiovascular causes rather than reaching dialysis, and here the icosapent ethyl data from REDUCE-IT are relevant though not kidney-specific. One consistent practical benefit is reduced triglycerides, which are commonly elevated in kidney disease.

    No studies are yet linked to both Omega-3 Fatty Acids and Chronic Kidney Disease.

    Safety

    Caveats

    High doses increase bleeding risk, which matters more in uraemic platelet dysfunction and around dialysis access procedures. Choose purified products, since some fish oils carry heavy metal contamination. Does not replace ACE inhibitors, ARBs or SGLT2 inhibitors.

    Less likely to help if

    People expecting filtration rate preservation, and those with advanced disease where the priority is standard therapy optimisation.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.